Last updated on June 2019

A Study of Parsaclisib in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)


Brief description of study

This is a Phase 2, open-label, 2-cohort study designed to evaluate the efficacy and safety of 2 parsaclisib treatment regimens in subjects with relapsed or refractory mantle cell lymphoma (MCL) previously treated either with or without a Bruton's tyrosine kinase (BTK) inhibitor.

Clinical Study Identifier: NCT03235544

Find a site near you

Start Over

St Joseph Heritage Healthcare

Santa Rosa, CA United States
  Connect »

ASCLEPES Research Centers

Brooksville, FL United States
  Connect »

Moffitt Cancer Center

Tampa, FL United States
  Connect »

Hattiesburg Clinic

Hattiesburg, MS United States
  Connect »

Clinical Research Alliance

New Hyde Park, NY United States
  Connect »

Kaiser Permanente Northwest

Portland, OR United States
  Connect »

Gettysburg Cancer Center

Gettysburg, PA United States
  Connect »

USOR - Texas Oncology

Austin, TX United States
  Connect »

USOR - Texas Oncology

San Antonio, TX United States
  Connect »

Renovatio Clinical

The Woodlands, TX United States
  Connect »

USOR - Texas Oncology

Tyler, TX United States
  Connect »

Ch Jolimont

La Louvière, Belgium
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

Centre Hospitalier Lyon-Sud

Pierre-Bénite Cedex, France
  Connect »

Gustave Roussy

Villejuif, France
  Connect »

Kliniken Maria Hilf

Moenchengladbach, Germany
  Connect »

Ch Jolimont

La Louvière, Belgium
  Connect »

Centre Hospitalier Lyon-Sud

Pierre-Bénite Cedex, France
  Connect »

Ch Jolimont

La Louvière, Belgium
  Connect »

Centre Hospitalier Lyon-Sud

Pierre-Bénite Cedex, France
  Connect »

Ch Jolimont

La Louvière, Belgium
  Connect »

Centre Hospitalier Lyon-Sud

Pierre-Bénite Cedex, France
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.